Consistent with these studies, our findings indicated that troxerutin might improve hepatic glucose disorders, including the enhancement of gluconeogenesis via its anti-obesity effect and consequent elevation of circulating adiponectin in HFD-treated mouse. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.